Sign in

CIK 0001740279

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

IN8BIO, INC.

Sign in to watch
Ticker
INAB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
825462585
Phone
+1 646-600-6438
Business address
EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
Former names
Incysus Therapeutics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Open-market buy Director bought 25,000 shares at $2.02 ($50,535)
  3. 4 Open-market buy Director bought 25,000 shares at $2.02 ($50,535)
  4. 4/A Derivatives Options or other derivatives
  5. 4/A Derivatives Options or other derivatives
  6. 4/A Derivatives Options or other derivatives
  7. 4/A Derivatives Options or other derivatives
  8. 4/A Derivatives Options or other derivatives
  9. 4 Open-market buy Director bought 51,214 shares at an average $2.02 ($103,340)
  10. 4 Open-market buy Director bought 51,214 shares at an average $2.02 ($103,340)
  11. 4 Open-market buy Director bought 50,000 shares at $1.93 ($96,500)
  12. 4 Open-market buy Director bought 50,000 shares at $1.93 ($96,500)
  13. 4 Open-market buy Director bought 789,473 shares at $1.90 ($1,499,999)
  14. 4 Open-market buy President, CEO and CFO bought 26,315 shares at $1.90 ($49,999)
  15. 4 Open-market buy Chief Operating Officer bought 5,263 shares at $1.90 ($10,000)
  16. 4 Open-market buy Chief Financial Officer bought 5,263 shares at $1.90 ($10,000)
  17. 4 Open-market buy Chief Medical Officer bought 2,631 shares at $1.90 ($4,999)
  18. 4 Open-market buy EVP and CSO bought 526 shares at $1.90 ($999)
  19. 4 Open-market buy Director bought 526 shares at $1.90 ($999)
  20. 4 Open-market buy Director bought 26,315 shares at $1.90 ($49,999)

Page 7 of 10 · 185 filings